Health Sciences Acquisitions Corporation 2 (Nasdaq: HSAQ, the "Company" or "HSAC 2") announced today that it closed its initial public offering of 16,000,000 ordinary shares, which included the full exercise of the underwriters' over-allotment option.
RTW Investments, a global, full life-cycle investor provides a multi-faceted capital solution to support Cytokinetics’ development of CK-274; including direct equity investment, royalty monetization, and royalty-backed development funding.
The RTW Charitable Foundation (“RTWCF”) is pleased to announce it has made three donations in May and June 2020. RTWCF was particularly motivated to rally around organizations providing relief to those affected by the COVID-19 pandemic.
With vast swathes of the world in lockdown, the one question on everyone’s minds is how long will it take to develop a vaccine against COVID-19? The Association of Investment Companies (AIC) has spoken to investment company and VCT managers about the prospects for a vaccine and how their portfolio companies are contributing to the fight against coronavirus.
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.